Mechanism of immunotherapy and progress in immunotherapy of breast cancer

doi:10.3877/cma.j.issn.1674-0785.2020.11.001

Abstract

Abstract:

Tumorigenesis and tumor progression are inseparable from the tumor ecosystem consisting of the tumor itself and its microenvironment. The clinical translation from bench to bedside can help breast oncologists develop more comprehensive and effective treatment strategies for breast cancer. The rise of immunotherapy is changing the pattern of systemic treatment of breast cancer. Combination of immunotherapy with traditional treatment can further improve the prognosis of breast cancer patients. In the future, discovering new targets and more accurate predictive biomarkers for anti-tumor immunotherapy are of importance to improve the clinical effect of immunotherapy for breast cancer patients.

Key words: Tumor ecosystem, Breast cancer, Immune evasion, Immunotherapy

Chang Gong, Qun Lin, Erwei Song. Mechanism of immunotherapy and progress in immunotherapy of breast cancer[J]. Chinese Journal of Clinicians(Electronic Edition), 2020, 14(11): 857-861.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcyszz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0785.2020.11.001

https://zhlcyszz.cma-cmc.com.cn/EN/Y2020/V14/I11/857

References 28

1	Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting [J]. Annu Rev Immunol, 2004, 22: 329-60.
2	DuPage M, Mazumdar C, Schmidt LM, et al. Expression of tumour-specific antigens underlies cancer immunoediting [J]. Nature, 2012, 482(7385): 405-409.
3	Alspach E, Lussier DM, Miceli AP, et al. MHC-II neoantigens shape tumour immunity and response to immunotherapy [J]. Nature, 2019, 574(7780): 696-701.
4	Marty R, Kaabinejadian S, Rossell D, et al. MHC-I genotype restricts the oncogenic mutational landscape [J]. Cell, 2017, 171(6): 1272-1283.
5	Seo H, Jeon I, Kim BS, et al. IL-21-mediated reversal of NK cell exhaustion facilitates anti-tumour immunity in MHC class I-deficient tumours [J]. Nat Commun, 2017, 8: 15776.
6	Rillahan CD, Paulson JC. Glycan microarrays for decoding the glycome [J]. Annu Rev Biochem, 2011, 80: 797-823.
7	O'Donnell JS, Teng MWL, Smyth MJ. Cancer immunoediting and resistance to T cell-based immunotherapy [J]. Nat Rev Clin Oncol, 2019, 16(3): 151-67.
8	Rooney MS, Shukla SA, Wu CJ, et al. Molecular and genetic properties of tumors associated with local immune cytolytic activity [J]. Cell, 2015, 160(1-2): 48-61.
9	El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial [J]. Lancet (London, England), 2017, 389(10088): 2492-2502.
10	Chihara N, Madi A, Kondo T, et al. Induction and transcriptional regulation of the co-inhibitory gene module in T cells [J]. Nature, 2018, 558(7710): 454-459.
11	Martinet L, Smyth MJ. Balancing natural killer cell activation through paired receptors [J]. Nat Rev Immunol, 2015, 15(4): 243-254.
12	Dong MB, Wang G, Chow RD, et al. Systematic immunotherapy target discovery using genome-scale in vivo CRISPR screens in CD8 T cells [J]. Cell, 2019, 178(5): 1189-1204.
13	Barkal AA, Brewer RE, Markovic M, et al. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy [J]. Nature, 2019, 572(7769): 392-396.
14	Li T, Li X, Zamani A, et al. c-Rel is a myeloid checkpoint for cancer immunotherapy [J]. Nature Cancer, 2020, 1(5): 507-517.
15	Yang L, Liu Q, Zhang X, et al. DNA of neutrophil extracellular traps promotes cancer metastasis via CCDC25 [J]. Nature, 2020, 583(7814): 133-138.
16	Goldman B, DeFrancesco L. The cancer vaccine roller coaster [J]. Nat Biotechnol, 2009, 27(2): 129-139.
17	Vonderheide RH, LoRusso PM, Khalil M, et al. Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells [J]. Clin Cancer Res, 2010, 16(13): 3485-3494.
18	Bernstein MB, Krishnan S, Hodge JW, et al. Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach? [J]. Nat Rev Clin Oncol, 2016, 13(8): 516-524.
19	Ho AY, Barker CA, Arnold BB, et al. A phase 2 clinical trial assessing the efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer [J]. Cancer, 2020, 126(4): 850-860.
20	Maeda K, Hazama S, Tokuno K, et al. Impact of chemotherapy for colorectal cancer on regulatory T-cells and tumor immunity [J]. Anticancer Res, 2011, 31(12): 4569-4574.
21	Limagne E, Euvrard R, Thibaudin M, et al. Accumulation of MDSC and Th17 cells in patients with metastatic colorectal cancer predicts the efficacy of a FOLFOX-Bevacizumab drug treatment regimen [J]. Cancer Res, 2016, 76(18): 5241-5252.
22	Khallouf H, Märten A, Serba S, et al. 5-Fluorouracil and interferon-α immunochemotherapy enhances immunogenicity of murine pancreatic cancer through upregulation of NKG2D ligands and MHC class I [J]. J Immunother, 2012, 35(3): 245-253.
23	Kang C, Syed YY. Atezolizumab (in combination with Nab-Paclitaxel): A review in advanced triple-negative breast cancer [J]. Drugs, 2020, 80(6): 601-607.
24	Schmid P, Adams S, Rugo H S, et al. Atezolizumab and Nab-Paclitaxel in advanced triple-negative breast cancer [J]. N Engl J Med, 2018, 379(22): 2108-2121.
25	Lee JS, Ruppin E. Multiomics prediction of response rates to therapies to inhibit programmed cell death 1 and programmed cell death 1 ligand 1 [J]. JAMA Oncol, 2019, 5(11): 1614-1618.
26	Bonneville R, Krook MA, Kautto EA, et al. Landscape of microsatellite instability across 39 cancer types [J]. JCO Precis Oncol, 2017, 2017: PO.17.00073.
27	Chowell D, Morris LGT, Grigg CM, et al. Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy [J]. Science, 2018, 359(6375): 582-587.
28	Lee JH, Long GV, Menzies AM, et al. Association between circulating tumor DNA and pseudoprogression in patients with metastatic melanoma treated with anti-programmed cell death 1 antibodies[J]. JAMA Oncol, 2018, 4(5): 717-721.

[1]	Hua Shao, Ziyue Na, Hui Jing, Bo Li, Qiucheng Wang, Wen Cheng. Value of preoperative percutaneous contrast-enhanced ultrasound in diagnosis of axillary sentinel lymph node metastasis and burden in breast cancer [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(08): 849-853.
[2]	Xu Zhang, Jianping Xu, Dongming Su, Caifen Wang, Dali Wang, Wenzhi Zhang. Contrast-enhanced ultrasound features of male breast masses [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(08): 854-859.
[3]	Chenxi Li, Xiaorong Tan, Wei Wei, Muqiu Li, Zhongcheng Gong. Characteristics and significance of tertiary lymphoid structures in oral cancer [J]. Chinese Journal of Stomatological Research(Electronic Edition), 2023, 17(05): 315-321.
[4]	Dechen Wang, Kang Yang, Zijie Yang, Mingbin Gui, Lianping Qu, Xiaofeng Zhang, Feng Gao. Progress of microsatellite stability state and PD-1/PD-L1/IDO in colorectal carcinoma [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(06): 462-465.
[5]	Yongting Xue, Feng Gao, Yanan Wang, Lianping Qu. Application of oncolytic virus therapy in colorectal cancer [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(05): 380-384.
[6]	Jia Yan, Shuangchi Liu, Zhengyu Wang. Progress in the research and application of tumor markers for gallbladder cancer [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(05): 391-394.
[7]	bing Feng, Qiuguo Zou, Zhenbo Liang, Yanming Lu, Yi Zeng, Shumiao Wu. Clinical study of ultrasonic signs and molecular biological indicators of senile non-specific invasive breast cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(01): 48-51.
[8]	Yansong Li, Huimin Feng, Mingchao Liu, Zepeng Liu, Qiuxia Jiang. Expression and clinical significance of STIP1 in triple negative breast cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(01): 52-56.
[9]	Runzhi Chen, Dongmei Yang, Huiting Xu. PD-1 combined with surufatinib for the treatment of metastatic colon cancer with microsatellite stability and BRAF V600E mutation: A case report and review [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(05): 431-435.
[10]	Baoru Hu, Naijian Shang, Di Gao. DCE-MRI and DWI findings of advanced hepatocellular carcinoma and their correlation with prognosis after immunotherapy [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(06): 399-403.
[11]	Liu Yang, Lanqun Qin, Qian Geng, Dongqing Li, Chunjian Qi, Hua Jiang. Predictive value of efficacy and prognosis of soluble immune checkpoints for immunotherapy in patients with gastric cancer [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(05): 305-311.
[12]	Ruixue Yue, Lingxin Kong, Xin Hao, Jinqiang Yang, Meng Han, Guozhong Cui, Jianjun Wang, Zhisheng Zhang, Fanting Kong, Wei Zhang, Wenbo He, Xianqiao Li, Xinping Zhou, Donghong Xu, Chongzhu Hu. HER2 protein expression levels predict efficacy of neoadjuvant therapy in breast cancer: A real-world study [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(07): 765-770.
[13]	Fei Liu, Yingxin Wang, Xing Ma, Ling Xin, Yuanjia Cheng, Qian Liu, Yue Wang, Junjun Zhang. Different conductive media for intracavitary electrocardiogram-guided arm port implantation among breast cancer patients: a randomized controlled trial [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(07): 760-764.
[14]	Meisha Fu, Yuhua Zhou, Hui Li, Chunyan Xue. Effect of lymphocyte immunotherapy on T lymphocyte subset distribution and PD1/PD-L1 expression in patients with recurrent miscarriage [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(06): 726-730.
[15]	Qiyue Zhang, Xiaodong Wang. Progress in understanding of relationship between IL-8 and tumor immunity [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(05): 605-613.

Please choose a citation manager

Content to export